Peptide Graded

Exenatide

Is Exenatide legal in the US?

Yes, FDA approved for type 2 diabetes. It is not approved for weight loss.

AStrong human evidenceFDA approvedas of 2026-10-26

Approved, with the brand products discontinued. Exenatide was approved by the FDA in 2005 as Byetta (twice-daily) and in 2012 as Bydureon (weekly; later Bydureon BCise) for glycemic control in type 2 diabetes. AstraZeneca discontinued Bydureon BCise and Byetta in the US in 2024 for business reasons; the approvals remain in force and generic exenatide is available. Exenatide has never been approved for weight loss. 13

Yes, for type 2 diabetes. Byetta was approved in 2005 and Bydureon in 2012. The brand products were discontinued in the US in 2024. But the approvals stand. Generic exenatide is on the market. 13

No. It never had a dedicated obesity trial. It produced only 2 to 3 kg of weight loss in diabetes trials. The GLP-1 drugs approved for obesity are liraglutide, semaglutide and tirzepatide. 1456

Read the full Exenatide page

More on Exenatide

Citations

  1. FDA 2024: Bydureon BCise (exenatide extended-release) prescribing information accessdata.fda.gov
  2. Furman 2012, Toxicon: the development of Byetta (exenatide) from the venom of the Gila monster pubmed.ncbi.nlm.nih.gov
  3. UnitedHealthcare 2024: discontinuation of Bydureon BCise and Byetta uhcprovider.com
  4. Pi-Sunyer 2015, NEJM: a randomized controlled trial of liraglutide in weight management (SCALE) doi.org
  5. Wilding 2021, NEJM: once-weekly semaglutide in adults with overweight or obesity (STEP 1) doi.org
  6. Jastreboff 2022, NEJM: tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) doi.org
  7. FDA 2025: Mounjaro (tirzepatide) prescribing information accessdata.fda.gov
  8. Holman 2017, NEJM: effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL) doi.org

Reference information only, not medical advice. Drawn from the Exenatide article, fact-checked against the cited sources. No dosing anywhere on this site.